Plexium Inc. and AbbVie Inc. entered into an exclusive strategic collaboration to develop and commercialize novel Targeted Protein Degradation (TPD) therapeutics for neurological conditions.
The most obvious risks from COVID-19 are hospitalization and death. But study after study shows the disease comes with an increased risk of a number of health problems, including diabetes.
The U.S. Food and Drug Administration approved Azurity Pharmaceuticals Inc.’s Fleqsuvy (baclofen oral suspension), 25 mg per 5 mL (5 mg/mL), Concentrated Formulation for the treatment of spasticity from multiple sclerosis or patients with spinal cord injuries and other spinal cord diseases.
Neurocrine Bioscience and Acadia Pharmaceuticals posted positive top-line results from their respective Phase III trials on major neurological diseases.
Johnson & Johnson will launch the newly approved drug Ponvory for adults with relapsing multiple sclerosis (MS) in the United States during early April 2021 at a similar price point to rival treatments, the company’s Janssen Pharmaceutical unit said on March 19.
California-based GW Pharmaceuticals initiated the company’s first U.S. Phase III trial studying nabiximols, which is known as Sativex outside the United States, as a potential treatment for multiple sclerosis-associated spasticity.
Federal authorities charged 10 former National Football League players for allegedly defrauding a healthcare program of more than $3.4 million by filing false claims for expensive medical equipment.
Allergan’s Botox was given the green light from the U.S. FDA to treat pediatric patients with lower limb spasticity.
Magnolia Neurosciences, co-founded by Accelerator Life Science Partners and The University of Texas MD Anderson Cancer Center, launched with a $31 million Series A financing.
